Head and neck cancer chemoprevention gets a shot in the arm

Journal of Clinical Oncology

Volumn 26, Issue 3, 2008, Pages 345-347

  Khuri, Fadlo R ^a   Shin, Dong M ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; BETA CAROTENE; BIOLOGICAL MARKER; BOWMAN BIRK INHIBITOR; CELECOXIB; CURCUMIN; EPICATECHIN; EPICATECHIN 3 GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; ERLOTINIB; GREEN TEA EXTRACT; ISOTRETINOIN; PODOPLANIN; POLYPHENOL; RETINOID; RETINOL PALMITATE; SELENIUM; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG MEGADOSE; EDITORIAL; HEAD AND NECK CANCER; HUMAN; LEUKOPLAKIA; MONOTHERAPY; NONHUMAN; POMEGRANATE JUICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MEMBRANE GLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 38649135051     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.0913     Document Type: Editorial

References (35)

1. Hong WK: Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets. J Clin Oncol 18:9S-18S, 2000
2. Hirsch F, Lippman SM: Advances in the biology of lung cancer chemoprevention. J Clin Oncol 23:3186-3197, 2005
3. Lippman SM, Lee JJ, Karp DD, et al: Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage-I non-small cell lung cancer. J Natl Cancer Inst 93:605-618, 2001
4. Shin DM, Khuri FR, Murphy B, et al: Combined interferon-alfa, 13-cisretinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: Novel bioadjuvant phase II trial. J Clin Oncol 19:3010-3017, 2001
5. Khuri FR, Lee JJ, Lippman SM, et al: Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98:441-450, 2006
6. Curfman GD, Morrissey S, Drazen JM: "Retraction: Sudbø J et al: DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 344:1270-1278, 2001 and Sudbø J et al: The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350:1405-1413, 2004." N Engl J Med 355:1927, 2006
7. Abbruzzese JL, Lippman SM: The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 6:321-326, 2004
8. Wolbach SB, Howe PR: Tissue changes following deprivation of fat-soluble vitamin A. J Exp Med 42:597-630, 1925
9. Slaughter DP, Southwick HM, Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6:963-968, 1953
10. Auerbach O, Hammond EC, Garfinkel L: Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. N Engl J Med 300:381-385, 1979
11. Hong WK, Endicott J, Itri LM, et al: 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
12. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
13. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al: Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-360, 2008
14. Spitz MR, Hong WK, Amos CI, et al: A risk model for prediction of lung cancer. J Natl Cancer Inst 99:715-726, 2007
15. Sporn MB, Dunlop NM, Newton DL, et al: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues [retinoids]. Fed Proc 35:1332-1338, 1976
16. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035, 1994
17. Omenn GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996
18. Mukhtar H, Ahmad N: Tea polyphernols: Prevention of cancer and optimizing health. Am J Clin Nutr 71:1698A-1702S, 1703S-1704S.
19. Yang CS, Maliakal P, Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42:25-54, 2002
20. Clinical Development Plan: Tea extracts, green tea polyphenols, epigallocatechin gallate. J Cell Biochem 26:236-257, 1996 (suppl)
21. Suganuma M, Sueoka E, Sueoka N, et al: Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-alpha expression. Biofactors 13:67-72, 2000
22. Chow HH, Hakim IA, Vining DR, et al: Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin Cancer Res 11:4627-4633, 2005
23. Imai K, Suga K, Nakachi K: Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 26:769-775, 1997
24. Pisters KW, Newman RA, Coldman B, et al: Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19:1830-1838, 2001
25. Schwartz JL, Baker V, Larios E, et al: Molecular and cellular effects of green tea on oral cells of smokers: A pilot study. Mol Nutr Food Res 49:43-51, 2005
26. Seeram NP, Adams LS, Henning SM, et al: In vitro anitproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 16:360-367, 2005
27. Adams LS, Seeram NP, Aggarwal BB, et al: Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem 54:980-985, 2006
28. Pantuck AJ, Leppert JT, Zomorodian N, et al: Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12:4018-4026, 2006
29. Trock BJ, Hilakivi-Clark L, Clarke R: Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 98:459-471, 2006
30. Yavelow J, Collins M, Birk Y, et al: Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro. Proc Natl Acad Sci U S A 82:5395-5399, 1985
31. Armstrong WB, Kennedy AR, Wan XS, et al: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6:4684-4691, 2000
32. Choe MS, Zhang X, Shin HJ, et al: Interaction between EGFR signaling and COX-2 pathways and its therapeutic implications. Mol Cancer Ther 4:1448-1455, 2005
33. Zhang X, Chen X, Choe MS, et al: Tumor growth inhibition by simultaneously blocking EGFR and cyclo-oxygenase-2 in a xenograft model. Clin Cancer Res 11:6261-6269, 2005
34. Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885, 2000
35. Rudin CM, Cohen EEW, Vassiliki A, et al: An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21:4546-4552, 2003